Page 58 - 2019食藥署年報(英文版)

'JHVSF cc 5BJXBO "4&"/ ESVH SFHVMBUPSZ GPSVN XPSLTIPQ QIPUP

3 to 6, 2018, inviting Malaysia, Philippines, Thailand, Vietnam, Indonesia and Regional
Comprehensive Economic Partnership(RCEP) countries India and other ASEAN national
authorities to come to Taiwan to share the current management status of drug administration in

the participating countries.
In order to deepen the exchanges between drug regulatory authorities, the forum was held
in a variety of formats such as expert meetings, workshops, information exchange meetings, on-
site visits and symposiums. The topics of the workshops included "Biologics, Biosimilars and
Vaccines" (Figure 3-8). The title of the symposium was "Regulation on Biologics, Biosimilars
and Vaccines" (Figure 3-9). In addition, we also invited the representatives of the ASEAN drug
regulatory authorities to visit the Division of Research and Analysis of TFDA and the vaccine

and biopharmaceutical plants in Taiwan.

0VUDPNFT BOE #FOFGJUT VUDPNFT BOE #FOFGJUT
0
4USFOHUIFO DPPQFSBUJPO XJUI .BMBZTJBO /BUJPOBM 1IBSNBDFVUJDBM

3FHVMBUPSZ "HFODZ

With the signing of the cooperation agreement on pharmaceutical management, to
strengthen cooperation with Malaysian National Pharmaceutical Regulatory Agency. TFDA
continues to actively facilitate the hominization of Malaysian pharmaceutical regulations,
LQVSHFWLRQ WHFKQRORJ\ H[FKDQJH DQG FRRSHUDWLRQ LQ WKH FHUWL¿FDWLRQ RI ODERUDWRU\ PDQDJHPHQW

to enhance the confidence level in Malaysia and countries of the New Southbound Policy in
Taiwan’s pharmaceutical products, so to reduce the trial testing, inspection, simplify the drug
review process and shorten the time for Taiwan’s pharmaceutical products to enter the countries
of the New Southbound Policy such as Malaysia, which will facilitate the connection between
UHJLRQDO PDUNHWV EHQH¿W WKH UHODWHG LQGXVWULHV LQ 7DLZDQ

56